Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ67Q0)

Drug Name

WT1 peptide vaccine Drug Info

Synonyms

WT1 peptide vaccine (cancer); WT1 peptide vaccine (cancer), Charity Medical School of the Humboldt University of Berlin; Cancer vaccine (Wilms tumor gene 1 + KLH + GM-CSF advuvants), Humboldt University of Berlin

Indication

Disease Entry	ICD 11	Status	REF
leukaemia	2A60-2B33	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMZ67Q0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Wilms tumor protein (WT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Combined PR1/WT1 vaccine	DMGCTX5	Myeloid leukaemia	2B33.1	Phase 2	[3]
WT1-targeted autologous dendritic cell vaccine	DMNFZYE	Acute myeloid leukaemia	2A60	Phase 2	[4]
FPI-01	DMXOTMP	Acute myeloid leukaemia	2A60	Phase 2	[5]
WT-4869	DM3FIMD	leukaemia	2A60-2B33	Phase 1/2	[6]
GSK-2130579A	DMRXW9P	Acute myeloid leukaemia	2A60	Phase 1	[7]
INNO-305	DMG6S8U	Acute myeloid leukaemia	2A60	Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Wilms tumor protein (WT1)	TTZ8UT4	WT1_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01266083) Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). U.S. National Institutes of Health.
2	Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer ImmunolImmunother. 2012 Mar;61(3):313-22.
3	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42.
4	ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health.
5	Clinical pipeline report, company report or official report of Formula Pharmaceuticals.
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385)
7	Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753)